长链非编码RNA PVT1作为癌症预后的有力预测指标：一项荟萃分析

Long Noncoding RNA PVT1 as a Potent Predictor of Prognosis in Cancers: a Meta-Analysis.

作者信息

Pan Xuefeng, Li Baohui, Fan Naijun, Li Juntang, Cai Fengbo, Zhao Guang, Zheng Guobao, Gao Chunfang

出版信息

Clin Lab. 2017 Oct 1;63(10):1657-1666. doi: 10.7754/Clin.Lab.2017.170418.

DOI:10.7754/Clin.Lab.2017.170418

PMID:29035442

Abstract

BACKGROUND

Plasmacytoma variant translocation 1 (PVT1), an oncogenic long noncoding RNA located in a recognized cancer-risk gene region-8q24, is significantly overexpressed in various cancers. Many studies have found that high expression of PVT1 was correlated with poor prognosis.

METHODS

This meta-analysis was performed by searching electronic databases Pubmed, Web of Science, Chinese National Knowledge Infrastructure, WanFang, and ChongQing VIP for eligible papers on the prognostic impact and clinicopathological characteristics of PVT1 expression in cancer from inception to January 31, 2017. The hazard ratio (HR) and odds ratio (OR) with 95% confidence intervals (CI) were computed to estimate the pooled effect of PVT1 on prognosis of cancers using Stata 12.0 version software.

RESULTS

Thirteen studies were finally included in this review with a total of 1559 patients. The pooled result indicated that overexpressed PVT1 predicts a poorer prognosis of cancerous patients for overall survival (HR = 1.91, 95% CI: 1.61 - 2.26, p < 0.001) and disease-free survival (HR = 1.90, 95% CI: 1.46 - 2.48, p < 0.001) or recurrencefree survival (HR = 1.77, 95% CI: 1.24 - 2.52, p = 0.002) or progression-free survival (HR = 2.84, 95% CI: 1.67 - 4.82, p < 0.001). High expression of PVT1 was closely associated with tumor-node-metastasis (TNM) stage (III/IV vs. I/II: OR = 3.19, 95% CI: 2.43 - 4.18, p < 0.001), and the significant correlation between PVT1 expression and TNM stage is found in T classification (T3/4 vs. T1/2: OR = 6.48, 95% CI: 2.93 - 14.31, p < 0.001) and lymph node metastasis (present vs. absent: OR = 2.56, 95% CI:1.36 - 4.80, p = 0.003), but not in distant metastasis of patients with cancers (yes vs. no: OR = 2.50, 95% CI: 0.72 - 8.66, p = 0.15). Furthermore, the cancerous patients with high PVT1 expression had a worse histological differentiation than those with low PVT1 expression (undifferentiated/poorly vs. moderately/well: OR = 1.48, 95% CI: 1.02 - 2.14, p = 0.039).

CONCLUSIONS

PVT1 could serve as a potent predicator of prognosis in different types of cancers.

摘要

背景

浆细胞瘤易位变异体1（PVT1）是一种致癌性长链非编码RNA，位于公认的癌症风险基因区域8q24，在多种癌症中显著过表达。许多研究发现，PVT1高表达与预后不良相关。

方法

通过检索电子数据库PubMed、Web of Science、中国知网、万方和维普，查找从创刊至2017年1月31日关于PVT1表达在癌症中的预后影响及临床病理特征的符合条件的论文，进行这项荟萃分析。使用Stata 12.0版本软件计算风险比（HR）和比值比（OR）以及95%置信区间（CI），以评估PVT1对癌症预后的综合影响。

结果

本综述最终纳入13项研究，共1559例患者。汇总结果表明，PVT1过表达预示着癌症患者总体生存（HR = 1.91，95% CI：1.61 - 2.26，p < 0.001）、无病生存（HR = 1.90，95% CI：1.46 - 2.48，p < 0.001）、无复发生存（HR = 1.77，95% CI：1.24 - 2.52，p = 0.002）或无进展生存（HR = 2.84，95% CI：1.67 - 4.82，p < 0.001）的预后较差。PVT1高表达与肿瘤-淋巴结-转移（TNM）分期密切相关（III/IV期与I/II期：OR = 3.19，95% CI：2.43 - 4.18，p < 0.001），并且在T分类（T3/4期与T1/2期：OR = 6.48，95% CI：2.93 - 14.31，p < 0.001）和淋巴结转移（有与无：OR = 2.56，95% CI：1.36 - 4.80，p = 0.003）中发现PVT1表达与TNM分期存在显著相关性，但在癌症患者的远处转移中未发现（有与无：OR = 2.50，95% CI：0.72 - 8.66，p = 0.15）。此外，PVT1高表达的癌症患者组织学分化比PVT1低表达的患者差（未分化/低分化与中分化/高分化：OR = 1.48，95% CI：1.02 - 2.14，p = 0.039）。